Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniela Toneatto

Showing results (11-20 of 50) with videos related to

Pageof 5
Sort By:
Lancet (London, England)|January 18, 2013
Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trialsTimo Vesikari, Susanna Esposito, Roman Prymula, et al.
Human Vaccines & Immunotherapeutics|March 31, 2018
Four-year antibody persistence and response to a booster dose of a pentavalent MenABCWY vaccine administered to healthy adolescents and young adultsXavier Sáez-Llorens, Johnny Beltran-Rodriguez, Jose M Novoa Pizarro, et al.
Human Vaccines & Immunotherapeutics|November 27, 2014
A phase 2 randomized controlled trial of a multicomponent meningococcal serogroup B vaccine, 4CMenB, in infants (II)Susanna Esposito, Roman Prymula, Gian Vincenzo Zuccotti, et al.
The Pediatric Infectious Disease Journal|January 13, 2018
Immune Responses to Booster Vaccination With Meningococcal ABCWY Vaccine After Primary Vaccination With Either Investigational or Licensed Vaccines: A Phase 2 Randomized StudyLeszek Szenborn, Stan L Block, Teresa Jackowska, et al.
Human Vaccines & Immunotherapeutics|January 17, 2018
Safety and immunogenicity of a meningococcal B recombinant vaccine when administered with routine vaccines to healthy infants in Taiwan: A phase 3, open-label, randomized studyNan-Chang Chiu, Li-Min Huang, Arnold Willemsen, et al.
Vaccine|May 22, 2007
Immunogenicity, safety and tolerability of meningococcal C CRM197 conjugate vaccine administered 3, 5 and 11 months post-natally to pre- and full-term infantsSusanna Esposito, Barbara Corbellini, Samantha Bosis, et al.
Vaccine|August 1, 2018
Breadth of coverage against a panel of 110 invasive disease isolates, immunogenicity and safety for 2 and 3 doses of an investigational MenABCWY vaccine in US adolescents - Results from a randomized, controlled, observer-blind phase II studyJo Anne Welsch, Shelly Senders, Brandon Essink, et al.
Vaccine|August 19, 2003
Antibody responses and HIV-1 viral load in HIV-1-seropositive subjects immunised with either the MF59-adjuvanted influenza vaccine or a conventional non-adjuvanted subunit vaccine during highly active antiretroviral therapyAnna M Iorio, Daniela Francisci, Barbara Camilloni, et al.
Vaccine|August 2, 2015
Immune responses to a recombinant, four-component, meningococcal serogroup B vaccine (4CMenB) in adolescents: a phase III, randomized, multicentre, lot-to-lot consistency studyKirsten P Perrett, Jodie McVernon, Peter C Richmond, et al.
Vaccine|November 12, 2018
Immunogenicity and safety of the 4CMenB and MenACWY-CRM meningococcal vaccines administered concomitantly in infants: A phase 3b, randomized controlled trialMercedes Macias Parra, Angela Gentile, Jorge Alejandro Vazquez Narvaez, et al.
Pageof 5

Showing results (11-20 of 50) with videos related to

Sort By:
Pageof 5
Lancet (London, England)|January 18, 2013
Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trialsTimo Vesikari, Susanna Esposito, Roman Prymula, et al.
Human Vaccines & Immunotherapeutics|March 31, 2018
Four-year antibody persistence and response to a booster dose of a pentavalent MenABCWY vaccine administered to healthy adolescents and young adultsXavier Sáez-Llorens, Johnny Beltran-Rodriguez, Jose M Novoa Pizarro, et al.
Human Vaccines & Immunotherapeutics|November 27, 2014
A phase 2 randomized controlled trial of a multicomponent meningococcal serogroup B vaccine, 4CMenB, in infants (II)Susanna Esposito, Roman Prymula, Gian Vincenzo Zuccotti, et al.
The Pediatric Infectious Disease Journal|January 13, 2018
Immune Responses to Booster Vaccination With Meningococcal ABCWY Vaccine After Primary Vaccination With Either Investigational or Licensed Vaccines: A Phase 2 Randomized StudyLeszek Szenborn, Stan L Block, Teresa Jackowska, et al.
Human Vaccines & Immunotherapeutics|January 17, 2018
Safety and immunogenicity of a meningococcal B recombinant vaccine when administered with routine vaccines to healthy infants in Taiwan: A phase 3, open-label, randomized studyNan-Chang Chiu, Li-Min Huang, Arnold Willemsen, et al.
Vaccine|May 22, 2007
Immunogenicity, safety and tolerability of meningococcal C CRM197 conjugate vaccine administered 3, 5 and 11 months post-natally to pre- and full-term infantsSusanna Esposito, Barbara Corbellini, Samantha Bosis, et al.
Vaccine|August 1, 2018
Breadth of coverage against a panel of 110 invasive disease isolates, immunogenicity and safety for 2 and 3 doses of an investigational MenABCWY vaccine in US adolescents - Results from a randomized, controlled, observer-blind phase II studyJo Anne Welsch, Shelly Senders, Brandon Essink, et al.
Vaccine|August 19, 2003
Antibody responses and HIV-1 viral load in HIV-1-seropositive subjects immunised with either the MF59-adjuvanted influenza vaccine or a conventional non-adjuvanted subunit vaccine during highly active antiretroviral therapyAnna M Iorio, Daniela Francisci, Barbara Camilloni, et al.
Vaccine|August 2, 2015
Immune responses to a recombinant, four-component, meningococcal serogroup B vaccine (4CMenB) in adolescents: a phase III, randomized, multicentre, lot-to-lot consistency studyKirsten P Perrett, Jodie McVernon, Peter C Richmond, et al.
Vaccine|November 12, 2018
Immunogenicity and safety of the 4CMenB and MenACWY-CRM meningococcal vaccines administered concomitantly in infants: A phase 3b, randomized controlled trialMercedes Macias Parra, Angela Gentile, Jorge Alejandro Vazquez Narvaez, et al.
Pageof 5